कंपनी का अवलोकन
Co-Diagnostics, Inc. functions as a specialized entity within the healthcare sector, specifically focusing on the medical devices industry by developing, manufacturing, and selling reagents for diagnostic tests that detect nucleic acid molecules in the United States and internationally. The company's core operations center around the Co-Dx PCR platform, which serves as its primary product offering for analyzing biological samples to support clinical decision-making processes. This organization currently maintains a market capitalization of $5.19M and employs a workforce of 115 individuals to support its research and manufacturing activities. With a trailing twelve-month revenue of $622,489, the company operates as a micro-cap enterprise, indicating a relatively small market presence compared to established peers in the molecular diagnostics space. The modest scale of annual revenue relative to its market cap suggests that the valuation is driven more by potential growth prospects or strategic assets rather than current profitability or massive revenue generation.
वित्तीय स्वास्थ्य
The company reported a revenue of $622,489 over the trailing twelve months, yet it recorded a net income of $-46,895,936 and an EBITDA of $-30,176,544, revealing a severe structural divergence where operating expenses vastly exceed top-line generation. The free cash flow stands at $-19,684,820, which indicates that the company is currently consuming cash reserves to fund its operations and product development rather than generating surplus liquidity for debt repayment or shareholder returns. While the gross margin remains healthy at 64.3%, reflecting efficient production costs relative to sales, the operating margin is a negative 2902.3% and the profit margin is 0.0%, signaling that overhead costs and research expenditures are consuming nearly all revenue before reaching the bottom line. The balance sheet shows a cash position of $11.88M against total debt of $1.24M, resulting in a debt-to-equity ratio of 5.99, which suggests a highly leveraged capital structure despite the substantial cash on hand. This leverage is further contextualized by a current ratio of 3.87, indicating that the company holds sufficient current assets to cover its short-term liabilities with nearly four times the margin required for immediate liquidity needs. However, the return on equity is -125.9% and the return on assets is -44.3%, metrics that demonstrate the company is currently destroying shareholder value and utilizing assets inefficiently in the absence of positive earnings.
मूल्यांकन आकलन
The valuation metrics present a complex picture where the P/E ratio (TTM) is N/A due to negative earnings, while the forward P/E is listed as -0.12, implying that the market is pricing in significant future earnings expansion or a turnaround in profitability to justify the current stock price. The price-to-book ratio of 0.15 indicates that the market values the company at significantly less than its accounting book value, suggesting a deep discount often found in distressed or high-growth pre-profitability biotech firms. Alternative valuation measures such as the price-to-sales ratio of 8.33 and the EV/EBITDA of 0.18 suggest that the market is willing to pay a premium for revenue growth despite the lack of current earnings, valuing the company primarily on its sales trajectory and potential. The stock has exhibited extreme volatility over the past year, trading between a 52-week high of $46.50 and a 52-week low of $1.35, meaning the current valuation sits within a range that reflects high uncertainty and speculative sentiment. With a beta of 1.43, the stock is expected to be 43% more volatile than the broader market, highlighting the significant price swings investors may encounter relative to large-cap indices.
Growth & Income
Revenue growth for the year over year is a robust 76.7%, whereas earnings growth is N/A, indicating that top-line expansion is currently outpacing any potential profitability improvements as the company burns cash to scale its operations. As the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a capital allocation strategy of reinvesting all available cash flow back into research, development, and manufacturing capacity rather than distributing income to shareholders. This reinvestment approach is typical for early-stage diagnostic companies aiming to capture market share and perfect their Co-Dx PCR platform before achieving sustainable profitability. The overall growth and income profile is defined by aggressive revenue expansion coupled with significant cash burn and a complete absence of dividend income, creating a high-risk, high-reward dynamic for capital providers.